Story
Eli Lilly's Oral Obesity Drug Foundayo Captures Over 30% of New US Patients
Summary
Eli Lilly announced its oral weight-loss drug Foundayo has secured over 30% of new US patient prescriptions, directly challenging the market leadership of Novo Nordisk's Wegovy pill.
Eli Lilly (LLY) announced its oral obesity treatment, Foundayo, has captured more than 30% of new patient prescriptions in the U.S. market, marking a significant challenge to the early dominance of rival Novo Nordisk (NVO). The update signals intensifying competition in the rapidly growing weight-loss drug sector.
Challenging Novo Nordisk's Lead
Speaking at the Morgan Stanley healthcare conference on Monday, Lilly Executive Vice President Ilya Yuffa disclosed the market share figure. The number indicates a substantial gain for Foundayo, narrowing the lead held by Novo Nordisk's Wegovy pill.
In August, Novo Nordisk CEO Mike Doustdar estimated that the oral version of Wegovy had captured about 90% of the country's oral obesity market. Lilly's recent gains suggest a more competitive landscape is emerging for tablet-based treatments, which are seen as a key growth area.
Market Impact and Growth
Investors are closely monitoring the adoption of oral obesity drugs, which could significantly expand the market by attracting patients who are hesitant to use injectable therapies. This format may also help alleviate the supply chain constraints that have affected popular injectable drugs.
AdAnalysts project the total market for obesity treatments could exceed $100 billion annually in the U.S. alone by 2030. Novo Nordisk itself has forecast that oral GLP-1 treatments could constitute more than a third of the weight-loss market by that year. Yuffa also noted that Lilly's injectable drug, Zepbound, has seen strong uptake in a Medicare pilot program, with 60% to 70% of enrollees being new to these types of treatments.
Global Competition
Beyond the U.S., Yuffa addressed the emergence of generic competition for Novo Nordisk's drugs in markets like India and Canada. He stated that while the launch of lower-cost generics can reduce market share, it also expands the overall patient pool.
Yuffa added that despite this competition, the absolute sales volume for Mounjaro, Lilly's brand for the same drug outside the U.S., continues to grow in those markets. This suggests that the increasing awareness and accessibility of GLP-1 treatments are driving overall market growth for all players.
Read next
More on Stocks
Record Diesel Prices Squeeze US Farmers, Threaten Higher Food Inflation
US farmers are facing record-high diesel costs during the crucial harvest season, a development that is squeezing profit margins and expected to push consumer food prices higher across the supply chain.
US Draft Rules to Permit Most Pharma Licensing Deals with China, Sources Say
The U.S. Treasury Department is reportedly drafting rules that would allow American pharmaceutical companies to continue most licensing deals with Chinese firms, sources say, avoiding broad restrictions sought by some lawmakers over national security concerns.
Century Aluminum's $4B Oklahoma Smelter Project Stalled by Local Opposition
A proposed $4 billion aluminum smelter in Oklahoma, backed by Century Aluminum and Emirates Global Aluminium, faces a prolonged local moratorium and a public referendum, creating significant uncertainty despite a key political victory for its supporters.
BofA Upgrades Equinor to 'Buy' on Bullish European Gas Price Forecast
BofA Securities raised its rating on Equinor to "Buy" from "Neutral," citing an improved outlook for European gas prices that is expected to significantly boost the energy company's cash flow. The bank also increased its price target to 465 Norwegian kroner.